Eine Studie zu Atezolizumab bei Teilnehmenden mit PD-L1-positivem, lokal fortgeschrittenem oder metastatischem nicht-kleinzelligem Lungenkarzinom (PD-L1: programmierter Zelltod-Ligand 1)

• Adult participants greater than or equal to 18 years of age
• Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
• Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
• PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
• Measurable disease, as defined by RECIST version 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:

Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1

• Central nervous system (CNS) disease, including treated brain metastases
• Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
• History of autoimmune disease
• History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted
• Active hepatitis B or hepatitis C
• Human Immunodeficiency virus (HIV) positive
• Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents